Arcutis Biotherapeutics Inc. (ARQT): Price and Financial Metrics


Arcutis Biotherapeutics Inc. (ARQT): $20.99

1.33 (+6.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARQT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARQT Stock Price Chart Interactive Chart >

Price chart for ARQT

ARQT Price/Volume Stats

Current price $20.99 52-week high $29.37
Prev. close $19.66 52-week low $13.59
Day low $19.20 Volume 834,700
Day high $21.31 Avg. volume 286,520
50-day MA $19.71 Dividend yield N/A
200-day MA $19.31 Market Cap 1.08B

Arcutis Biotherapeutics Inc. (ARQT) Company Bio


Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.


ARQT Latest News Stream


Event/Time News Detail
Loading, please wait...

ARQT Latest Social Stream


Loading social stream, please wait...

View Full ARQT Social Stream

Latest ARQT News From Around the Web

Below are the latest news stories about Arcutis Biotherapeutics Inc that investors may wish to consider to help them evaluate ARQT as an investment opportunity.

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment of the sole pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitisEnrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitis and roflumilast foam in scalp and body psoriasisSecured $225 million in non-dilutive debt financing from SLR Capital Partners, further strengthenin

Yahoo | February 22, 2022

Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a price target of $58.00. The company's shares closed last Tuesday at $15.61, close to its 52-week low of $13.59. According to TipRanks.com, Ear 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 36.4% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, uniQure, and Avrobio. Currently, the analyst consensus on Arcutis Biotherapeutics is a Moderate Buy with an average price target of $46.50.

Howard Kim on TipRanks | February 8, 2022

Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis

Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023A total of 457 subjects are enrolled in the STRATUM studySeborrheic dermatitis affects 10 million people in the U.S. WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its STRATUM

Yahoo | February 1, 2022

Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) today and set a price target of $58.00. The company's shares closed last Friday at $17.41, close to its 52-week low of $14.16. According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.2% and a 28.6% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Avrobio, and uniQure. Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $46.50. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $38.49 and a one-year low of $14.16.

Howard Kim on TipRanks | January 18, 2022

10 Small-Cap Stocks to Buy According to Billionaire Steve Cohen

In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […]

Yahoo | January 10, 2022

Read More 'ARQT' Stories Here

ARQT Price Returns

1-mo 3.96%
3-mo 17.92%
6-mo 26.67%
1-year -20.34%
3-year N/A
5-year N/A
YTD 1.21%
2021 -26.27%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5301 seconds.